RMND5A

Across TCGA pan-cancer cohorts, RMND5A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RMND5A data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RMND5A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RMND5A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, ESCA, and LUSC are the cancer types where RMND5A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.282	0.692	.014	18	view →
ESCA	OS	Median	All	0.372	0.707	.001	15	view →
LUSC	OS	Median	All	0.131	0.776	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.487	.043	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RMND5A–OV (OS)

Open the OV breakdown →